INTREXON CORPORATION (NYSE:XON) Files An 8-K Results of Operations and Financial Condition

INTREXON CORPORATION (NYSE:XON) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

Attached as Exhibit 99.1 is a copy of a press release of Intrexon Corporation, dated May10, 2018, reporting its financial results for the quarter ended March31, 2018.

Such information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 2.02 Regulation FD Disclosure.

On May10, 2018, Intrexon Corporation provided slides to accompany its earnings presentation. A copy of the slides is furnished as Exhibit 99.2 hereto.

Such information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 2.02 Financial Statements and Exhibits.


INTREXON CORP Exhibit
EX-99.1 2 d568653dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Intrexon Announces First Quarter 2018 Financial Results – Quarterly GAAP revenues of $43.8 million and net loss attributable to Intrexon of $42.0 million including non-cash charges of $26.3 million – – Adjusted EBITDA of $(19.7) million – GERMANTOWN,…
To view the full exhibit click here

About INTREXON CORPORATION (NYSE:XON)

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.

An ad to help with our costs